polyclonal goat anti-human cxcl10, ccl4, or ccl5 primary antibody  (R&D Systems)

Journal: Frontiers in Immunology

Article Title: Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc + Monocytes in Rectal Cancer

doi: 10.3389/fimmu.2019.00602

Figure Lengend Snippet: Rectal cancer-infiltrating pDCs can express CXCL10 and CCL4. (A,B) Immunofluorescence stainings were conducted to analyze the presence of CXCL10- or CCL4-expressing pDCs in 9 pre-nRCT and 18 post-nRCT tumor specimens of the matched cohort. As representative examples, images of single (A) CXCL10 and BDCA-2 or single (B) CCL4 and BDCA-2 stainings as well as merged images are shown. Original magnification was x200.

Article Snippet: For the two-color Opal staining, the BDCA-2 primary antibody was used together with the polyclonal goat anti-human CXCL10, CCL4, or CCL5 primary antibody (1:100, all from R&D Systems, low pH retrieval) and combined with the TSA fluorophores 650 (1:100) and 570 (1:100), respectively.

Techniques: Immunofluorescence, Expressing

Journal: International journal of oncology

Article Title: Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer.

doi: 10.3892/ijo.2011.1247

Figure Lengend Snippet: Figure 2. (a), Scattergram of serum CXCL10 in stage I-IV colorectal cancer patients and control subjects (p<0.0001). (b), Scattergram of serum CXCL10 subdivided by pathological T stage (p=0.0101). (c), Scattergram of serum CXCL10 subdivided by clinical H stage (p=0.0004). (d), The relationships between serum CXCL10 and serum CEA level (r=0.2853, p<0.0001).

Article Snippet: Primary anti-CXCL10 goat polyclonal antibody (clone AF976, R&D Systems, MN, USA) and anti-CXCR3 rabbit polyclonal antibody (clone ab8023, Abcam, Cambridge, UK) at a dilution of 1:25 were used for the labeled streptavidinbiotin method (LASB2 kit/HRP, Dako Cytomation).

Techniques: Control

Journal: International journal of oncology

Article Title: Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer.

doi: 10.3892/ijo.2011.1247

Figure Lengend Snippet: Figure 3. (a), Cancer specific survival curves, for 218 patients with colorectal cancer, according to serum CXCL10 level. Patients with higher serum CXCL10 had significantly poorer prognoses than those with lower serum CXCL10 levels (p<0.0001, log-rank test); cut-off value = 199 pg/ml. (b), Cancer specific survival curves for 163 patients in stage I-III with curative intent, according to serum CXCL10 level. Patients with higher serum CXCL10 also had significantly poorer prognoses than those with lower serum CXCL10 levels (p=0.0372, log-rank test); cut-off value = 153 pg/ml.

Article Snippet: Primary anti-CXCL10 goat polyclonal antibody (clone AF976, R&D Systems, MN, USA) and anti-CXCR3 rabbit polyclonal antibody (clone ab8023, Abcam, Cambridge, UK) at a dilution of 1:25 were used for the labeled streptavidinbiotin method (LASB2 kit/HRP, Dako Cytomation).

Techniques:

Journal: International journal of oncology

Article Title: Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer.

doi: 10.3892/ijo.2011.1247

Figure Lengend Snippet: Figure 4. CXCL10 protein expression was assessed using immunohistochemistry in normal mucosa with primary CRC (a), primary colorectal cancer (b) and liver metastasis tissue (c). Magnification, x40. Scale bar = 500 µm.

Article Snippet: Primary anti-CXCL10 goat polyclonal antibody (clone AF976, R&D Systems, MN, USA) and anti-CXCR3 rabbit polyclonal antibody (clone ab8023, Abcam, Cambridge, UK) at a dilution of 1:25 were used for the labeled streptavidinbiotin method (LASB2 kit/HRP, Dako Cytomation).

Techniques: Expressing, Immunohistochemistry